EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, RUA Life Sciences's Enterprise Value is €7.92 Mil.
RUA Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 was €-2.25 Mil. Therefore, RUA Life Sciences's EV-to-FCF for today is -3.52.
The historical rank and industry rank for RUA Life Sciences's EV-to-FCF or its related term are showing as below:
FRA:AOHA'
s EV-to-FCF Range Over the Past 10 Years
Min: -54.57 Med: -5.07 Max: 19.08
Current: -3.41
During the past 13 years, the highest EV-to-FCF of RUA Life Sciences was 19.08. The lowest was -54.57. And the median was -5.07.
FRA:AOHA's EV-to-FCF is ranked worse than 100% of 356
companies
in the Medical Devices & Instruments industry
Industry Median: 26.16
vs FRA:AOHA: -3.41
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for RUA Life Sciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of RUA Life Sciences's EV-to-FCF
For the Medical Devices subindustry, RUA Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RUA Life Sciences's EV-to-FCF Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where RUA Life Sciences's EV-to-FCF falls into.
RUA Life Sciences's current Enterprise Value is €7.92 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RUA Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 was €-2.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RUA Life Sciences (FRA:AOHA) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
RUA Life Sciences's PE Ratio for today is calculated as:
RUA Life Sciences's share price for today is €0.11.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RUA Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was €-0.097.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
RUA Life Sciences EV-to-FCF Related Terms
Thank you for viewing the detailed overview of RUA Life Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
RUA Life Sciences PLC is a biomedical polymer technology, components, and medical device company. The company's principal activities comprise exploiting the value of its IP and know-how, medical device contract manufacturing, and development of cardiovascular devices. Its business segments are Royalty and License Income (Biomaterials), Contract Manufacture, Product Development (Vascular), and Product Innovation (Structural Heart). It derives the majority of its revenue from the Contract Manufacture segment. Geographically, it derives its major revenue from the USA and has a presence in Europe and the Rest of the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:AOHA has been successfully added to your 